ven-aza versus intensive chemotherapy as bridging therapy in patients with mds
Published 6 months ago • 104 plays • Length 2:18Download video MP4
Download video MP3
Similar videos
-
5:36
venetoclax and azacitidine in mds patients
-
4:44
establishing the clinical benchmark of azacitidine in patients with mds
-
1:22
responses to olutasidenib in patients with aml who have failed treatment with venetoclax
-
4:13
ven-a-qui: low-dose cytarabine or azacitidine venetoclax and quizartinib in older patients with aml
-
2:18
phase ib study of venetoclax plus azacitidine in patients with r/r mds
-
2:22
the efficacy of ven-aza salvage therapy compared to azacitidine monotherapy in r/r aml
-
7:50
which aml patients benefit most from venetoclax treatment?
-
4:52
apoptosis and venetoclax
-
6:13
how has acute myeloid leukemia treatment for elderly people changed in 2021?
-
2:30
real-world outcomes of venetoclax azacitidine versus intensive chemotherapy in newly diagnosed aml
-
1:45
deciding which patients with mpns are suitable candidates for interferon-based therapy
-
1:17
venetoclax plus azacitidine vs intensive chemotherapy induction in fit patients with aml
-
0:44
mds: an update on pevonedistat plus azacitidine
-
3:40
phase ii study of venetoclax and azacitidine vs induction chemotherapy in fit patients with aml
-
2:27
low-dose azacitidine and venetoclax as maintenance therapy in patients with aml
-
1:56
evaluating long-term survival in patients with aml who discontinued azacitidine-venetoclax
-
1:12
phase i study of ziftomenib with venetoclax or venetoclax/azacitidine or 7 3 in r/r aml
-
2:50
gilteritinib plus azacitidine versus azacitidine monotherapy for newly diagnosed flt3-mutated aml
-
1:42
nivolumab in combination with azacitidine in patients with relapsed acute myeloid leukemia (aml)
-
3:51
venetoclax plus azacitidine in treatment-naïve and r/r mds
-
1:24
omniverse: safety and tolerability of oral azacitidine plus venetoclax in patients with aml
-
1:50
treating patients with poor-risk cytogenetics with venetoclax and hmas